Novavax's COVID-19 Vaccine Gets OK In South Korea


Novavax Inc's NVAX COVID-19 vaccine has swung an OK in South Korea, where it will be manufactured and marketed by SK bioscience.

  • The shot will be available to adults 18 years and older. 
  • SK bioscience already has an advanced purchase agreement with the government for 40 million doses, according to Novavax.
  • "Novavax is proud to bring our COVID-19 vaccine to South Korea at a critical time in the pandemic as both the Delta and Omicron variants have taken hold," CEO Stanley Erck said in a statement.
  • Related: Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron.
  • The shot dubbed Nuvaxovid in South Korea has also received authorization from the WHO and in Europe, India, Indonesia, and the Philippines.
  • Novavax has still not filed with the FDA. At the end of 2021, Novavax submitted its complete chemistry, manufacturing, and controls (CMC) data package to the FDA.
  • The vaccine is also under review by multiple additional regulatory agencies worldwide, and it expects to receive additional worldwide authorizations in 1H of 2022. 
  • On Wednesday, the company said it was still a month away from filing in the US.
  • Price Action: NVAX shares are down 0.68% at $129.79 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!